Authors :
Vrind B. Oza; Dr. Khushbu K. Patel; Dr. C. N. Patel; Dr. Pruthviraj K. Chaudhary
Volume/Issue :
Volume 10 - 2025, Issue 1 - January
Google Scholar :
https://tinyurl.com/3fstrymv
Scribd :
https://tinyurl.com/2mffkmrx
DOI :
https://doi.org/10.5281/zenodo.14716934
Abstract :
Hypercholesterolemia, is a condition that
increase cholesterol levels in body and it is major risk
factor for cardiovascular disease (CVD). In the treatment
of this condition statins, bile acid sequestrants, and
cholesterol absorption inhibitors are use but they show
side effects especially statin are cause muscle-related
complications. Bempedoic acid is new drug that lower the
lipid and it is alternative of other medicine. It is use in
statin-intolerant patients or those with familial
hypercholesterolemia. Bempedoic acid inhibit ATP-
citrate lyase which is produce factor of cholesterol and
reduce level of LDL-C without any muscle-related
adverse effects which are show in statins. This review
article explores Bempedoic acid’s mechanism of action, its
clinical efficacy in management of hypercholesterolemia,
and its potential as a complementary or alternative
therapy to traditional lipid-lowering treatments. Given its
unique mechanism, Bempedoic acid offers a valuable
advancement in the pharmacological management of
hypercholesterolemia and cardiovascular risk.
Keywords :
Bempedoic Acid, Hypercholesterolemia, Cholesterol Management, LDL-C Reduce.
References :
- Mithun J Varghese (2014) “Familial hypercholesterolemia: A review”. Annals of pediatric cardiology ;7: page no. 107-17.
- P Barton Duell et al. (2024) “Efficacy and safety of Bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials”. Journal of clinical lipidology ;18: page no. e153-e165.
- Anthony Markham (2020) “Bempedoic Acid: First Approval”. Drugs ;80: page no. 747-753.
- PubChem (10472693), (2024) “Bempedoic acid”, https://pubchem.ncbi.nlm.nih.gov/compound/Bempedoic-Acid
- Ramyashree Tummala et al. (2022) “Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis”. Annals of medicine ;54: page no. 1287-1296.
- Jadhav, S.B. et al. (2023) “Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia”. J. Pharmacokinet. Pharmacodyn. 50, page no. 351–364.
- Medscape (2024) “Bempedoic acid”. https://reference.medscape.com/drug/nexletol-bempedoic-acid-1000354
- Laufs U et al. (2019) "Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia and statin intolerance." J. Am. Heart Assoc. ;8: 1-13.
- Chandramahanti S (2024) “Bempedoic Acid”. StatPearls https://www.ncbi.nlm.nih.gov/books/NBK594232/
- Drug bank (DB11936), (2024) “Bempedoic acid”. https://go.drugbank.com/drugs/DB11936
Hypercholesterolemia, is a condition that
increase cholesterol levels in body and it is major risk
factor for cardiovascular disease (CVD). In the treatment
of this condition statins, bile acid sequestrants, and
cholesterol absorption inhibitors are use but they show
side effects especially statin are cause muscle-related
complications. Bempedoic acid is new drug that lower the
lipid and it is alternative of other medicine. It is use in
statin-intolerant patients or those with familial
hypercholesterolemia. Bempedoic acid inhibit ATP-
citrate lyase which is produce factor of cholesterol and
reduce level of LDL-C without any muscle-related
adverse effects which are show in statins. This review
article explores Bempedoic acid’s mechanism of action, its
clinical efficacy in management of hypercholesterolemia,
and its potential as a complementary or alternative
therapy to traditional lipid-lowering treatments. Given its
unique mechanism, Bempedoic acid offers a valuable
advancement in the pharmacological management of
hypercholesterolemia and cardiovascular risk.
Keywords :
Bempedoic Acid, Hypercholesterolemia, Cholesterol Management, LDL-C Reduce.
